• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on The Walt Disney Co. (NYSE: DIS)

    6/5/25 1:58:00 PM ET
    $AMGN
    $DIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Get the next $AMGN alert in real time by email

    TROY, Mich., June 5, 2025 /PRNewswire/ -- Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August.

    The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Disney's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?studyid=16958122.

    A full report on Disney will appear in the August 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc.  (AMGN: NASDAQ), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-the-walt-disney-co-nyse-dis-302474596.html

    SOURCE NAIC-BetterInvesting

    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMGN
    $DIS

    CompanyDatePrice TargetRatingAnalyst
    Walt Disney Company
    $DIS
    7/16/2025$120.00 → $138.00Buy
    UBS
    Walt Disney Company
    $DIS
    6/30/2025$144.00Hold → Buy
    Jefferies
    Walt Disney Company
    $DIS
    6/3/2025$135.00 → $140.00Buy
    Rosenblatt
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Walt Disney Company
    $DIS
    4/21/2025$112.00Peer Perform → Outperform
    Wolfe Research
    Walt Disney Company
    $DIS
    1/22/2025$125.00Buy
    Citigroup
    Walt Disney Company
    $DIS
    1/7/2025$100.00 → $147.00Neutral → Buy
    Redburn Atlantic
    More analyst ratings

    $AMGN
    $DIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcdonald Calvin bought $999,994 worth of Disney Common Stock (11,756 units at $85.06), increasing direct ownership by 111% to 22,313 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      8/9/24 4:33:36 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Gorman James P bought $2,120,628 worth of Disney Common Stock (20,000 units at $106.03), increasing direct ownership by 4,283% to 20,467 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      5/9/24 7:06:37 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Chang Amy bought $99,918 worth of Disney Common Stock (1,078 units at $92.69), increasing direct ownership by 21% to 6,216 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      12/8/23 4:59:03 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AMGN
    $DIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

      NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

      7/21/25 7:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NYSE Content Advisory: Pre-Market update + The Walt Disney Company rings Opening Bell to celebrate Disneyland Resort's 70th anniversary

      NEW YORK, July 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Caroline Woods delivers the pre-market update on July 17th Stocks are pointing to a mixed open Thursday morning as investors track the latest developments involving President Trump and Fed Chair Jerome Powell. On Wednesday, markets finished a volatile session in the green.Traders will be eyeing the latest batch of earnings including reports from NYSE-Listed TSMC and Travelers. These results will offer insight into how executives are vie

      7/17/25 8:55:00 AM ET
      $DIS
      $ICE
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
      Investment Bankers/Brokers/Service
      Finance
    • The Walt Disney Company Executives to Discuss Fiscal Third Quarter 2025 Financial Results via Webcast

      The Walt Disney Company (NYSE:DIS) will host a live audio webcast to discuss fiscal third quarter 2025 financial results beginning at 8:30 a.m. ET / 5:30 a.m. PT on Wednesday, August 6, 2025. Disney will release results before the opening of regular trading on August 6, 2025 and post earnings materials at www.disney.com/investors. To listen to the webcast, please visit www.disney.com/investors. The webcast will be archived. Materials and webcast may include forward-looking information. View source version on businesswire.com: https://www.businesswire.com/news/home/20250702786800/en/ Carlos Gómez Investor Relations (818) 560-1933 David Jefferson Corporate Communications (818) 560-48

      7/2/25 1:00:00 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AMGN
    $DIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. EVP and Chief HR Officer Coleman Sonia L converted options into 1,167 units of Disney Common Stock and covered exercise/tax liability with 419 units of Disney Common Stock, increasing direct ownership by 61% to 1,971 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      7/18/25 6:33:12 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • EVP, Control, Fin Plan & Tax Woodford Brent converted options into 1,147 units of Disney Common Stock and covered exercise/tax liability with 253 units of Disney Common Stock, increasing direct ownership by 2% to 51,737 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      7/18/25 6:32:43 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • EVP, Control, Fin Plan & Tax Woodford Brent converted options into 1,930 units of Disney Common Stock and covered exercise/tax liability with 470 units of Disney Common Stock, increasing direct ownership by 3% to 50,843 units (SEC Form 4)

      4 - Walt Disney Co (0001744489) (Issuer)

      7/16/25 6:33:10 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AMGN
    $DIS
    SEC Filings

    See more
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:46:22 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 11-K filed by Amgen Inc.

      11-K - AMGEN INC (0000318154) (Filer)

      6/12/25 4:42:09 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Walt Disney Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Walt Disney Co (0001744489) (Filer)

      6/9/25 4:16:48 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AMGN
    $DIS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      11/21/24 12:43:07 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for PAVBLU issued to AMGEN INC

      Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

      8/26/24 5:53:38 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for REPATHA issued to AMGEN INC

      Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

      8/21/24 12:12:47 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      2/13/24 4:58:51 PM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Walt Disney Company (Amendment)

      SC 13G/A - Walt Disney Co (0001744489) (Subject)

      2/13/24 4:55:53 PM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

      SC 13G/A - AMGEN INC (0000318154) (Subject)

      1/30/24 11:35:57 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    Financials

    Live finance-specific insights

    See more
    • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

      At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.  Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal j

      6/30/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

      MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes  New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT  THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio

      6/18/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

      The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: https://www.multivu.com/amgen/9340551-en-amgen-barry-sanders-highlight-dangers-bad-cholesterol-new-documentary The Making of a Heart Attack features renowned former football running back, Barry Sanders, who reveals he expe

      6/13/25 9:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMGN
    $DIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS reiterated coverage on Walt Disney with a new price target

      UBS reiterated coverage of Walt Disney with a rating of Buy and set a new price target of $138.00 from $120.00 previously

      7/16/25 9:25:02 AM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Walt Disney upgraded by Jefferies with a new price target

      Jefferies upgraded Walt Disney from Hold to Buy and set a new price target of $144.00

      6/30/25 7:55:59 AM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Rosenblatt reiterated coverage on Walt Disney with a new price target

      Rosenblatt reiterated coverage of Walt Disney with a rating of Buy and set a new price target of $140.00 from $135.00 previously

      6/3/25 9:00:58 AM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AMGN
    $DIS
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

      NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

      7/21/25 7:00:00 AM ET
      $AMGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • The Walt Disney Company Launches Inaugural, Company-Wide "Disney Week of Wishes" Campaign to Celebrate World Wish Day With Make-A-Wish

      As the world's largest wish granter for Make-A-Wish, Disney grants a wish every hour of every day all year long Today, The Walt Disney Company (NYSE:DIS) kicks off a weeklong company-wide campaign to celebrate its 45-year relationship with Make-A-Wish® by launching the first ever "Disney Week of Wishes." During this unprecedented week, Disney is honoring World Wish Day on April 29 by sharing unique wishes selected by Make-A-Wish kids that only Disney can make come true. This includes a wish-granting moment on American Idol, a Princess-themed ball for nearly 50 families at Disney World, and making one girl's wish of meeting a star of the Marvel Cinematic Universe come true. The unique power

      4/28/25 10:00:00 AM ET
      $DIS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components